[Effect of BECN1 Expression on Proliferation and Invasion of Human Myeloma Cell Line RPMI-8226].

OBJECTIVE: To investigate the effect of BECN1 expression on proliferation and invasion of human multiple myeloma (MM) cell line RPMI-8226. METHODS: RPMI-8226 cells were cultured in vitro, the recombinant plasmid pcDNA3.1-BECN1 was constructed and transfected into RPMI-8226 cells, then the cells were divided into three groups: control group, negative transfection group and BECN1 transfection group. The expression of BECN1 mRNA in cells of each group was detected by real-time fluorescent quantitative polymerase chain reaction (qRT-PCR); the effect of BECN1 overexpression on cell proliferation inhibition rate was detected by cell counting kit 8 (CCK-8); the effect of BECN1 overexpression on the colony formation rate was detected by plate cloning assay; the effect of BECN1 overexpression on cell invasion was detected by Transwell assay; the effects of BECN1 overexpression on the expression of cell proliferation, invasion and autophagy-related proteins were detected by Western blot. RESULTS: The expression of BECN1 mRNA in BECN1 transfection group was significantly higher than that in control group and negative transfection group (P<0.05); the inhibition rate of cell proliferation and the expression of autophagy-related proteins Beclin1, Atg5 and invasion-related protein E-cadherin in BECN1 transfection group were significantly higher than those in control group and negative transfection group; the colony formation rate, invasion number and the expression of proliferation-related proteins CyclinD1, ß-catenin and invasion-related protein N-cadherin were significantly lower than those in control group and negative transfection group (P<0.05). CONCLUSION: Overexpression of BECN1 can inhibit the proliferation and invasion of human MM cells RPMI-8226, which may be a potential research target of MM.

The association of polymorphisms in TNF and ankylosing spondylitis in common population: a meta-analysis.

BACKGROUND: Studies investigating the association between the polymorphisms in TNF and ankylosing spondylitis have been reported the conflicting results. Here we performed a meta-analysis based on the evidence available from the literature up-to-date to further clarify this relationship. METHODS: Our systematic search was done in the PubMed, Embase and Cochrane databases (up to March 2020). The pooled and individual odds ratios (ORs) with 95% confidence intervals (CIs) of the minor allele of each locus were presented to assess the associations between TNF polymorphisms and AS in different ethnicities in common population. RESULTS: Seventeen studies, consisting of seven European studies, eight East Asian studies and two Latin-American studies, were included in this meta-analysis. In the total population, the A allele in TNF-238 (OR = 0.702, 95%CI = 0.506-0.973, p = 0.034) and TNF-308 (OR = 0.638, 95%CI = 0.507-0.804, p = 0.000), the C allele in TNF-1031 (OR = 0.594, 95%CI = 0.446-0.791, p = 0.000), the T allele in TNF-850 (OR = 3.462, 95%CI = 1.764-6.798, p = 0.000) and rs769178 (OR = 2.593, 95%CI = 2.175-3.091, p = 0.000) were significantly associated with AS susceptibility. There were no significant association between the minor alleles of TNF-376, TNF-857, TNF-863 and AS susceptibility. There are inconsistent results in the Latin-American population and East Asian population with those in the total population. CONCLUSIONS: Our meta-analysis suggests that TNF-α polymorphisms at positions - 238, - 308, - 850, - 1031 and rs769178 could have an influence on ankylosing spondylitis susceptibility in the total population. But there is no association of the TNF-376, TNF-857, TNF-863 polymorphisms with ankylosing spondylitis. Some results in the subgroups are not consistent with those in the total population.

[Therapeatic Efficacy of Decitabine on Low and Moderate-Risk MDS Patients and the Prognostic Factors].

OBJECTIVE: To investigate the efficacy of decitabine in the treatment of patients with low-risk and moderate-risk myelodysplastic syndrome (MDS) and to analyze the prognostic factors. METHODS: A retrospective study was conducted on 47 patients with low and moderate risk MDS treated with decitabine in our hospital. The course of treatment was 20 mg/(m2·d)×5 d injected subcutaneously for 28 d as a course of treatment. After 3 to 4 courses of treatment, the therapeutic response and survival prognostic factors of patients were evaluated. RESULTS: According to the revised IWG standard, 18 patients (38.3%) achieved CR, 13 patients (27.7%) achieved PR, 7 patients (14.9%) showed hematological improvement, 7 patients (14.9%) died of pulmonary infection or myelosuppression, 2 patients transformed into acute myeloid leukemia. The median survival time of MDS patients was 26 months. The overall effective rate of decitabine regimen was 80.9% (38/47). The independent poor prognostic factors for survival were high IPSS grade, long course of MDS, early treatment for MDS, and elder. CONCLUSION: The long-term efficacy of decitabine in the treatment of low and moderate-risk MDS is definite. The clinical factors before treatment may predict the efficacy of decitabine in the treatment of MDS.